Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.

ABSTRACT:

Objective

To generate comparative efficacy evidence of belimumab versus anifrolumab in SLE that can inform treatment practices.

Methods

The SLE Responder Index (SRI)-4 response at 52 weeks of belimumab versus anifrolumab was evaluated with an indirect treatment comparison. The evidence base consisted of randomised trials that were compiled through a systemic literature review.A feasibility assessment was performed to comprehensively compare the eligible trials and to determine the most appropriate indirect treatment comparison analysis method. A multilevel network meta-regression (ML-NMR) was implemented that adjusted for differences across trials in four baseline characteristics: SLE Disease Activity Index-2K, anti-double-stranded DNA antibody positive, low complement (C)3

SUBMITTER: Neupane B 

PROVIDER: S-EPMC10186457 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature